Does systemic treatment of psoriasis reduce the risk of comorbidities?

Gisondi, Paolo

doi:10.1111/bjd.18456

Cited by 4 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Obesity is associated with low-grade systemic inflammation because it drives metabolic and immunological pathways including Th17 cell differentiation. Moreover, obesity generates biomechanical stress at joints and entheses and triggers, via IL-23, psoriatic arthritis worsening [ 163 ].…”

Section: Need For An Integrated Model Of Psoriasis: Conclusion and Future Perspectivesmentioning

confidence: 99%

Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches

et al. 2021

View full text Add to dashboard Cite

Psoriasis is an immune-mediated inflammatory disease, with a chronic relapsing-remitting course, which affects 2–3% of the worldwide population. The progressive acquisitions of the inflammatory pathways involved in the development of psoriasis have led to the identification of the key molecules of the psoriatic inflammatory cascade. At the same time, psoriasis therapy has radically evolved with the introduction of target molecules able to modify the natural history of the disease, acting specifically on these inflammatory pathways. For these reasons, biologics have been demonstrated to be drugs able to change the disease’s natural history, as they reduce the inflammatory background to avoid irreversible organ damage and prevent systemic complications. However, several issues related to the use of biologics in patients with systemic comorbidities, remain open. All these data reflect the extraordinary potentiality of biologics, but also the unmet medical need to improve our knowledge on the long-term risk related to continuous use of these drugs, and their administration in special populations. This narrative review aims to highlight both the efficacy and safety profile of biologics in psoriasis, starting from pathophysiology and moving towards their clinical application.

show abstract

Section: Need For An Integrated Model Of Psoriasis: Conclusion and Future Perspectivesmentioning

confidence: 99%

Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches

et al. 2021

View full text Add to dashboard Cite

show abstract

Gastroenterological safety of IL-17 inhibitors: a systematic literature review

Caron

Jouzeau

Miossec

et al. 2021

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Comorbidity in Adult Psoriasis: Considerations for the Clinician

Daugaard¹,

Iversen²,

Hjuler³

2022

PTT

View full text Add to dashboard Cite

Psoriasis is associated with several comorbidities ranging from cardiovascular comorbidity and mental disorders to other immune mediated inflammatory diseases. However, most of these co-morbidities are often overlooked or diagnosed late. Furthermore, evidence suggests that comorbidities are undertreated. Here, we provide an overview of comorbidities in psoriasis and present a simple rundown of considerations of relevance to the clinician. We hope that this review may raise clinicians’ awareness of comorbidities in psoriasis and provide simple guidance regarding screening tools and treatment decisions in psoriasis with comorbidities.

show abstract

Does systemic treatment of psoriasis reduce the risk of comorbidities?

Abstract: Linked Article: Korman. Br J Dermatol 2020; 182:840–848.

Cited by 4 publications

References 8 publications

Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches

Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches

Gastroenterological safety of IL-17 inhibitors: a systematic literature review

Comorbidity in Adult Psoriasis: Considerations for the Clinician

Contact Info

Product

Resources

About